LLY trades at the lowest forward multiple in 18 months while net income has compounded from $5.2B in FY2023 to $20.6B in FY2025. The earnings line is running 2-3 quarters ahead of the multiple.
Eli Lilly printed FY2025 revenue of $65.2 billion, up 44.7% year on year. Net income climbed from $10.6 billion to $20.6 billion, a 95% increase that is, frankly, staggering for a $776 billion drug-manufacturer franchise. Operating income reached $29.7 billion against a base of $17.5 billion in FY2024, expanding the operating margin from 38.9% to 44.9%. Free cash flow swung from $414 million to $8.97 billion as the heavy capex cycle for capacity expansion began to roll off.
That is what an earnings inflection looks like in a major pharmaceutical franchise. The multiple has not kept pace. The trailing PE of 37.9x looks rich on the screen, but the forward PE has compressed to 25.7x as the FY2026 EPS estimate has marched higher faster than the share price. That 25.7x forward multiple is the lowest LLY has traded at in roughly 18 months, despite earnings power running at the highest absolute level the company has ever printed.
The Valuation Desk view is that the multiple-to-earnings gap is unsustainable for a franchise growing earnings at 40%+ on a structural demand backdrop that the GLP-1 category is still in the early innings of penetrating. Fair value at 28-30x forward earnings (reasonable for the growth profile) implies a stock price in the $1,000-$1,070 zone against a current $870 print. We are buyers at current levels and aggressive buyers below $830.
The risks are clear and bounded. Manufacturing capacity, competitive entry from Novo Nordisk's pipeline, and the eventual generic exposure on Trulicity are all real. None are large enough to offset the operating leverage on tirzepatide and the next-generation pipeline through FY2028. The math works.
The FY2025 earnings explosion was not an accounting curiosity. Three operational levers all contributed simultaneously, and the combination produced operating leverage that the Street consistently underestimated through three consecutive earnings cycles.
The first lever was tirzepatide volume growth. Mounjaro and Zepbound combined for an estimated $35-37 billion in FY2025 revenue, up from roughly $20 billion in FY2024. The category is still capacity-limited rather than demand-limited. Every incremental dose manufactured is an incremental dollar of revenue at gross margins exceeding 80%. The 5.2% gross margin expansion year on year (from 81.3% to 84.0% by Valuation Desk reconstruction of segment-level data) reflects the mix shift toward the GLP-1 franchise.
The second lever was operating cost leverage. Total operating expenses grew at roughly 19% versus revenue growth of 44.7%. The marketing and SG&A spend was already largely in place by mid-2024. The R&D line continued growing in absolute dollars but compressed as a percentage of revenue from 24% to 19%. That kind of operating leverage is normal for a franchise inflecting through its capacity curve.
The third lever was the capex roll-off. Capital expenditure totalled $7.84 billion in FY2025, down from $8.40 billion in FY2024. The peak capacity expansion phase, which absorbed roughly $24 billion of capex over 2023-2025, is past its midpoint. FCF margin therefore expanded from less than 1% in FY2024 to 13.8% in FY2025, with another 500-700 basis points of expansion modelled for FY2026 as capex normalises further. The cash conversion story is now compounding.
TickerXray Report
Get the complete Eli Lilly report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
The 25.7x forward PE looks like a normal large-cap pharma multiple. It is not, given the growth profile attached to it. A franchise growing earnings at 30%+ on multi-year visibility historically commands 30-35x forward earnings. The current level reflects two consensus concerns that the Valuation Desk views as overstated.
The first concern is GLP-1 competitive entry. The bear narrative is that oral semaglutide, retatrutide, and the broader Novo and Pfizer pipelines will compress LLY's category share by 2027-2028. The data on this is more nuanced than the narrative. Novo's pipeline candidates have shown competitive efficacy but not best-in-class profiles. The retatrutide phase III readouts have been positive but not category-disrupting. Tirzepatide's clinical positioning, dosing convenience, and label expansions (most recently into sleep apnoea and cardiovascular outcomes) keep it as the franchise asset for the next 24-36 months at minimum. Competitive concern is not zero, but it is not 2026 or 2027 either.
The second concern is manufacturing capacity. The bear case argues that LLY will hit production constraints that limit revenue upside even as demand grows. The capex disclosures suggest the opposite. Roughly 60% of the planned capacity additions are now operational, with another 30% commissioning through FY2026 and the final 10% online by mid-FY2027. The capacity curve is meeting the demand curve, not lagging it. The Q1 capacity comments on the most recent earnings call were the most confident the company has been in three years.
Net of those concerns, the multiple should be re-rating up to 28-30x forward, not staying flat at 25.7x. The math is simple. The Street has not yet caught up to the FY2026 earnings curve. The earnings revisions tell the story: consensus FY2026 EPS has moved from $32.50 in October 2025 to $34.20 in late February 2026. That trajectory will continue.
Consensus FY2026 EPS of $34.20 multiplied by a fair multiple of 28-30x yields $958-$1,026. Use a slightly higher confidence on the Valuation Desk's own EPS forecast of $36.50 (reflecting upside on tirzepatide volumes from the latest dosing-convenience launches), and the same multiple range yields $1,022-$1,095. Take the midpoint at roughly $1,025, which is 18% above the current $870 print.
Looking out further to FY2028, with EPS modelled at $48-52 (depending on competitive entry assumptions), and applying a more conservative 22-24x multiple to reflect maturing growth, fair value lands at $1,056-$1,248. The compounding profile from today's price is therefore double-digit annually for the next three years even on conservative assumptions.
The FCF yield framing matters too. FY2026 FCF is modelled at $14-15 billion, rising to $20 billion by FY2028. At today's $776 billion market cap, the FY2028 FCF yield is roughly 2.6%. That is not eye-popping in absolute terms but is excellent for a franchise growing FCF at 25%+ over the period. Compared to other large-cap pharma names trading at 4-5% FCF yields with 3-5% FCF growth, the relative value is clearly with LLY.
The analyst target price of $1,202 implied by the Street consensus is roughly aligned with the Valuation Desk fair value range. The Street has been consistently behind the curve on revising upward. Each of the past five quarterly prints has triggered consensus EPS uplifts in the 5-10% range. That pattern is the engine of the multiple recovery we see playing out through FY2026.
Compare LLY's forward PE of 25.7x to the broader large-cap pharma cluster. Novo Nordisk trades at roughly 23x forward, growing earnings at 18-20%. Merck sits at 13x forward, growing low double digits. AbbVie at 14x forward, low single digit growth. Pfizer at 9x, declining earnings on Comirnaty rolloff. The LLY multiple is the highest in the cluster, but it is the highest multiple attached to the highest growth rate.
Growth-adjusted, LLY's forward PEG (using the Valuation Desk forecast 30%+ FY2026 EPS growth) is roughly 0.85x. Novo Nordisk's PEG is 1.15x. Merck and AbbVie sit at 1.40-1.60x. Pfizer's PEG is not meaningful given negative growth. On growth-adjusted multiples, LLY is the cheapest large-cap pharma name in the world right now, despite carrying the largest absolute multiple.
The Ajax Therapeutics acquisition for up to $2.3 billion announced this month, expanding the oncology pipeline, is a small but positive read on management's discipline. The Valuation Desk has been watching for capital allocation discipline as the cash pile grows. A $2.3 billion bolt-on with clear strategic logic, rather than a $40 billion transformational deal that destroys value, is the right move. The pattern through the past three years has been disciplined, and the buyback line has continued at moderate pace alongside the bolt-on M&A. That balance keeps the per-share earnings power compounding.
The biggest risk to the cross-pharma comparison is a Novo pipeline win in oral semaglutide that compresses tirzepatide's premium positioning. We watch the readouts. As of today, the data does not point to that disruption arriving inside the 2026-2027 window.
Three things would force a re-rate down. First, a manufacturing supply-chain disruption that stalls tirzepatide volumes for two or more quarters. The historical base rate on multi-quarter manufacturing disruptions in major drug-manufacturing franchises is low (roughly 8% in any given 12-month window) but not zero. The capex investments have largely de-risked this, but the residual risk is real.
Second, a regulatory delay on tirzepatide label expansions. The cardiovascular outcomes data was strong, but the FDA label progression for related indications (NASH, MASH, sleep apnoea continuation) is a quarter-by-quarter process with normal regulatory uncertainty. A delay would not change the long-term thesis but would compress the near-term revenue acceleration.
Third, US drug pricing reform. The Inflation Reduction Act negotiation cycle includes some tirzepatide-adjacent products in the next round. The direct revenue impact is contained (the negotiated prices apply to Medicare prescriptions only, and tirzepatide commercial book is the larger share), but the multi-year overhang on US biopharma multiples is real. We model a 10% multiple compression over five years from this dynamic and still arrive at constructive fair value today.
None of these risks individually breaks the bull thesis. A combination of two or more, materialising inside 12 months, would be the trigger to reassess. We monitor each.
Eli Lilly at 25.7x forward earnings is mispriced against the earnings trajectory. The consensus FY2026 EPS estimate has been revised upward by roughly 25% over the past 12 months. The share price has moved up by less than that. The multiple has therefore compressed, opening the gap that we expect to close. Fair value lands at $1,025, with upside to $1,095 if FY2026 EPS prints above $36.
We are buyers at the current $870 print and aggressive buyers below $830. The setup is uncomplicated. The earnings power exists, the multiple has compressed, and the catalyst path (continued estimate revisions through FY2026) is well-defined.
The bear case is a competitive disruption that has not yet shown up in the clinical data. The bull case is the FCF inflection that is just beginning to compound. Today's price prices in too much of the bear case and too little of the bull case. That is the gap. We expect it to close inside 12 months as the FY2026 prints reset consensus and the multiple recovers toward the 28-30x zone the growth profile deserves.
The analytical pattern across pharma supercycles is consistent. The dominant earnings franchise re-rates in two phases. Phase one is the discovery of the demand curve (LLY went through this in 2023-2024). Phase two is the multiple expansion as the earnings deliver. We are mid-phase-two. The trade is to own the franchise now, ride the multiple recovery, and trim only above $1,100. We are buyers.
A final historical anchor. The last comparable earnings inflection in major pharma was Gilead through the Sovaldi launch in 2014-2015, where revenue grew 122% in a single year and the franchise compounded earnings at 50%+ for two years. Gilead re-rated from 11x forward to 14x forward at the peak of the inflection, then compressed as the Sovaldi tail rolled off. LLY's tirzepatide profile is structurally different. The patent runway is longer, the indication expansion broader, and the obesity tailwind not yet at saturation. The Gilead playbook was a two-year trade. The LLY playbook looks like a four-to-six year trade. We are early in it.
For portfolio managers running large-cap pharma allocations, the call here is straightforward. LLY remains the highest-quality growth franchise in the sector, with the cleanest near-term earnings trajectory and the strongest free cash flow inflection. The multiple is the cheapest it has been at any point in the past 18 months, despite the strongest earnings momentum the company has produced in its history. That combination is rare. We act on it.
Full forensic analysis of Eli Lilly
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
Lilly's revenue compounded 56% in the most recent quarter on a $30+ billion run-rate. The GLP-1 cycle is the most consequential pharmaceutical event since the statin era. The data behind the thesis.
LLY trades at 26.7x forward on GLP-1 growth. MRK trades at 22x forward on a Keytruda cliff. The Valuation Desk compares the two franchises on durability, pipeline, and execution to identify the next leg of pharma outperformance.
Medicare coverage changes on GLP-1s dominate the headlines. The non-obesity pipeline is where the next leg of Lilly's multiple sits.